In addition, a large number of clinical trials of Schuler et al. (5) found treatments with errotene, gefitinib, or afatinibthe in NSCLC with EGFR mutation would get a longer progress-free survival and higher objective response rate, compared with standard first-line chemotherapy. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.